Alnylam, with positive data on second gene-silencing drug, plans filing to FDA

Fresh off its first drug approval, Alnylam announced positive interim data from a trial of another gene-silencing treatment on Thursday and said it hopes to file with the Food and Drug Administration for accelerated approval of the drug, givosiran, likely by the end of the year.